Previously untreated patients were randomly assigned in a 2:1 ratio to receive either 12 weeks or 8 weeks of daclatasvir at a standard dose of 60 mg daily ( with dose adjustment for concomitant antiretroviral medications ) plus 400 mg of sofosbuvir daily .